Abcam, ab248097, Anti-GARS antibody [EPR7157] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal GARS antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human, Mouse, Rat samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR7157,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab248097 is the carrier-free version of
ab125008
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Glycyl-tRNA synthetase (GARS) also known as GlyRS is an enzyme involved in the protein synthesis process. GARS catalyzes the attachment of glycine to its corresponding transfer RNA (tRNA) enabling the correct integration of glycine into proteins during translation. It has a molecular mass of approximately 79 kDa and is ubiquitously expressed in many tissues including muscle and the nervous system. The enzyme plays a critical function by ensuring the accurate translation of the genetic code into functional proteins.
Biological function summary
GARS maintains the fidelity of protein synthesis ensuring that glycine gets incorporated into proteins correctly. As part of the aminoacyl-tRNA synthetase family it operates within a larger complex important for cellular protein production. GARS ensures that proteins maintain their proper structure and function by providing the correct amino acids during synthesis. Its activity supports cell survival and proper cellular functions across various tissues.
Pathways
The function of GARS is central in aminoacyl-tRNA biosynthesis and the broader protein synthesis pathway. This enzyme works closely with other aminoacyl-tRNA synthetases to ensure the fidelity of protein translation. Interactions with proteins such as EPRS (glutamyl-prolyl-tRNA synthetase) highlight the coordinated effort among different synthetases for efficient protein biosynthesis linking it to a fundamental cellular process essential for cellular viability and function.
Mutations in GARS have been associated with Charcot-Marie-Tooth disease type 2D and distal hereditary motor neuropathy type V. These genetic disorders result in peripheral neuropathy characterized by muscle weakness and sensory deficits. Mutated GARS disrupts normal glycine-tRNA ligation impacting neuronal function. These conditions often involve interactions with proteins like neurofilament proteins contributing to neurodegeneration.